Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 22, 2022 - Issue 12: Biological therapies for psoriasis
Submit an article Journal homepage
370
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience

Federico Bardazzia Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy;b Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna
,
Filippo Viviania Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy;b Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, BolognaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3606-292X
ORCID Icon,
Yuri Merlia Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy;b Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna
,
Vito Di Lerniac Dermatology Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
,
Francesca Peccerilloc Dermatology Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy
,
Andrea Contid Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, Dermatology Unit, University of Modena and Reggio Emilia, Modena, Italy
,
Claudia Lasagnid Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, Dermatology Unit, University of Modena and Reggio Emilia, Modena, Italy
,
Michela Tabanellie Dermatology Unit, AUSL della Romagna, Ravenna, Italy
,
Simone D’Adamioe Dermatology Unit, AUSL della Romagna, Ravenna, Italy
,
Sergio Di Nuzzof Dermatology, Department of Medicine and Surgery, University of Parma, Parma, Italy
,
Chiara Cortellazzif Dermatology, Department of Medicine and Surgery, University of Parma, Parma, Italy
&
Federica Filippia Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy;b Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, BolognaORCID Iconhttps://orcid.org/0000-0001-8173-4257
ORCID Icon show all
Pages 1561-1566 | Received 07 Feb 2022, Accepted 06 Apr 2022, Published online: 13 Apr 2022

References

  • Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007;25(6):535–546.
  • Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.
  • Blauvelt A, Papp KA, Griffiths CE, et al., Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
  • Langley RG, Tsai TF, Flavin S, et al., Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123.
  • Markham A. Guselkumab: first Global Approval. Drugs. 2017;77(13):1487–1492.
  • Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431.
  • Megna M, Fabbrocini G, Cinelli E, et al. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. J Dermatolog Treat. 2020;33(2):1–5.
  • TREMFYA - FULL PRESCRIBING INFORMATION. 15 January, 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761061s007lbl.pdf
  • European Medicines Agency. Tremfya (guselkumab). [cited 2022 January 15]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya
  • REGIONE EMILIA-ROMAGNA. Proposta: DPG/2019/1273 del 23/01/2019. AGGIORNAMENTO DICEMBRE 2018 DEL PRONTUARIO TERAPEUTICO REGIONALE (EMILIA-ROMAGNA REGION. Proposal: DPG/2019/1273 of 23/01/2019. DECEMBER 2018 UPDATE OF THE THERAPEUTIC HANDBOOK REGIONAL). 15 01, 2022. Available from: https://salute.regione.emilia-romagna.it/ssr/strumenti-e-informazioni/ptr/archivio/atti-regionali-e-documenti-ptr/Det1128del23_1_2019AggPTRdicembre2018.pdf
  • Benhadou F, Ghislain PD, Guiot F, et al. Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: a Belgian retrospective multicentre study. J Eur Acad Dermatol Venereol. 2020;34(12):e837–e9.
  • Fougerousse AC, Ghislain PD, Reguiai Z, et al. Effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis under real-life conditions: a retrospective multicenter study. J Eur Acad Dermatol Venereol. 2020;34(10):e644–e6.
  • Galluzzo M, Tofani L, Lombardo P, et al., Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9(7):2170.
  • Maliyar K, O’Toole A, Gooderham MJ. Long-term single center experience in treating plaque psoriasis with Guselkumab. J Cutan Med Surg. 2020;24(6):588–595.
  • Ruggiero A, Fabbrocini G, Cinelli E, et al. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti- interleukin −17 treatment: a real-life 52-week retrospective study. Dermatol Ther. 2021;34(1):e14673.
  • Snast I, Sherman S, Holzman R, et al. Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020;33(6):e13964.
  • Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115–1125.
  • Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126–1136.
  • Mease PJ, McInnes IB, Tam LS, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology (Oxford). 2021;60(5):2109–2121.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.